A Post Approval Safety Study (PASS): Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected with Chronic Hepatitis C Receiving a Long-Acting Interferon plus Ribavirin (GUARD-C) | HMA-EMA Catalogues of real-world data sources and studies